Turner Christopher Durant
Chief Medical Officer
Turner Christopher Durant has filed 2 SEC Form 4 filings (11 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Jul 15, 2026.
On the most recent filing, Turner Christopher Durant is listed as Chief Medical Officer at Nuvalent, Inc. Inside the rolling window, Turner Christopher Durant reported no open-market purchases and 2 open-market sales totaling $721K in NUVL. The largest disclosed transaction in the window is a sale of 4,236 NUVL shares on Jan 5, 2026, worth $412K.
Companies traded
Other insiders at NUVL
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$721K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Turner Christopher Durant made?
Turner Christopher Durant has filed 2 SEC Form 4 filings (11 transaction rows) across 1 company since 2026.
Which companies does Turner Christopher Durant trade?
Turner Christopher Durant has filed SEC Form 4 disclosures for 1 company, including NUVL.
When was Turner Christopher Durant's most recent SEC Form 4 filing?
Turner Christopher Durant's most recent SEC Form 4 filing on Tracefour is dated Jul 15, 2026.
What is Turner Christopher Durant's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Turner Christopher Durant is listed as Chief Medical Officer.
What is Turner Christopher Durant's total buy and sell value in the current window?
Inside the rolling retention window, Turner Christopher Durant bought $0 and sold $721K based on SEC Form 4 filings.
What was Turner Christopher Durant's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 4,236 NUVL shares on 2026-01-05, worth $412K, per SEC Form 4 filings.